All articles by Jay Patel

Jay Patel is a Pharma analyst with GlobalData.

Jay Patel

Industry slow to embrace new fatty liver disease nomenclature

The three societies voted by a supermajority for the shift, justifying their collective decision by suggesting that the new names were less stigmatising and exclusionary than their predecessors.

THR-β agonists emerge as leading drug class in NASH

Just this month, Terns Pharma released results from the Phase IIa DUET trial of its own THR-β agonist TERN-501.